Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates.
$3.34+24.16%
报价 2026-11-06
市值
$24.6M
EV
–
PE (TTM)
–
预期 PE
–
52 周区间距高点 -94.7%
$2.69$63.60
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Biotechnology| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| IMMPImmutep Limited | $24.6M | +24.2% | – | 85% | – | – | – | |
| ABVCABVC BioPharma, Inc. | $25.9M | -0.2% | +740.5% | 100% | – | – | – | |
| BYSIBeyondSpring Inc. | $25.7M | -1.0% | +41.1% | 0% | – | – | – | |
| AARDAardvark Therapeutics, Inc. Common Stock | $25.6M | +5.4% | – | 0% | – | – | – | |
| CVMCEL-SCI Corporation | $25.5M | +5.8% | +304.3% | 0% | – | – | – | |
| ALGSAligos Therapeutics, Inc. | $25.4M | -9.8% | +528.0% | 99.2% | – | – | – | |
| CELUCelularity Inc. | $24.7M | +4.8% | +76.0% | 19.2% | – | – | – | |
| NXTCNextCure, Inc. | $24.4M | +4.1% | -85.2% | 0% | – | – | – | |
| NSRXNasus Pharma Ltd. | $24.3M | -3.1% | – | 0% | – | – | – | |
| 同行中位数 | – | – | +190.1% | 0% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
报告货币 AUD（非美元）暂无季度数据（首次研究运行后填充）。